ID   Mel-SOE
AC   CVCL_C503
SY   EST97
DR   cancercelllines; CVCL_C503
DR   Cosmic; 1047659
DR   Cosmic; 2163867
DR   ESTDAB; ESTDAB-097
DR   GEO; GSM156006
DR   IARC_TP53; 26086
DR   Progenetix; CVCL_C503
DR   Wikidata; Q54905136
RX   PubMed=17260012;
RX   PubMed=23851445;
CC   Omics: Variations; Array-based CGH.
ST   Source(s): ESTDAB=ESTDAB-097
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D3S1358: 14,16
ST   D5S818: 11,12
ST   D7S820: 7,12
ST   FGA: 19,25
ST   TH01: 6,9.3
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 10-04-25; Version: 15
//
RX   PubMed=17260012; DOI=10.1038/sj.onc.1210252;
RA   Jonsson G., Dahl C., Staaf J., Sandberg T., Bendahl P.-O., Ringner M.,
RA   Guldberg P., Borg A.;
RT   "Genomic profiling of malignant melanoma using tiling-resolution
RT   arrayCGH.";
RL   Oncogene 26:4738-4748(2007).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//